ClinicalTrials.gg
CompletedNCT05796349Updated Apr 3, 2023

Study on Data Acquisition and Image Characteristics of Brain Multifrequency EIT in Healthy People and Patients With Brain Diseases

An observational study in Cerebral Hemorrhage, Cerebral Ischemia and Cerebral Edema, sponsored by Jieshi Ma. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by Jieshi Ma · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
24
Sex
All
01

Study summary

The goal of this observational study is to compare the differences in the features of cerebral multifrequency EIT(cMFEIT) images between healthy subjects and patients with brain diseases and to explore the possibility of applying multifrequency EIT to intracranial abnormality detection.16 healthy volunteers and 8 patients with brain diseases were recruited as experimental subjects, and the cerebral EIT data of 9 frequencies in the range of 21 kHz - 100 kHz of all subjects were acquired with an EH-300 MFEIT system.

Read the detailed description

For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps. The healthy group included 16 individuals (male, age 40.25±11.18). No history of brain disease and no abnormalities were seen on plain CT scans of their brains. Cerebral EIT data collection from healthy volunteers was performed in a dedicated laboratory with temperature controlled at 24±1 °C and 52%±1% humidity in 2022. The subjects were lying in a horizontal position. The patient group included 8 patients with brain diseases (7 males, age 59±10.46). Obvious lesions were visible on the patients' CT or MRI images, including 6 patients with intracranial hemorrhage, 1 patient with cerebral ischemia, and 1 patient with cerebral edema. Data from patients with brain diseases were collected at the neurosurgical intensive care unit at the Army Medical Center of PLA in 2022. The cerebral EIT data of the patients were collected in the same position as the healthy individuals. The MFEIT image sequence is obtained according to a certain imaging algorithm, and the ROI area ratio (AR_ROI) on the left and right sides of the image and the average value of the reconstructed ROI resistivity change (MVRRC_ROI) are extracted. Based on the extracted indicators, the geometric asymmetry index (GAI) and intensity asymmetry index (IAI) was further proposed to characterize the symmetry of MFEIT images, and the differences between the two groups of subjects on MFEIT images were statistically compared and analyzed.

02

Conditions studied

  • Cerebral Hemorrhage
  • Cerebral Ischemia
  • Cerebral Edema
  • Healthy

Keywords

  • Multifrequency electrical impedance tomography
  • Intracranial abnormality
  • Detection
  • Symmetry
03

In context

Cerebral Hemorrhage

457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.

This study's enrollment of 24 is below the median of 300 across 180 observational studies indexed under Cerebral Hemorrhage.

Browse Cerebral Hemorrhage studies →

Lead sponsor

This is the only study on the registry with Jieshi Ma as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Health Group: No history of brain disease and no abnormalities were seen on plain CT scans of their brains.

Patient Group: Obvious lesions were visible on the patient's CT or MRI images.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Health Group: No history of brain disease and no abnormalities were seen on plain CT scans of their brains.
  2. Patient Group: Patients with cerebral hemorrhage, cerebral ischemia, and cerebral edema, less than 12 days after onset.

Exclusion criteria

Exclusion Criteria:

  1. Health Group:

    • Neurological diseases such as epilepsy, brain tumors, and cerebral vascular malformations;
    • Neurological symptoms such as headache and dizziness;
    • Abnormal signals detected on CT.
  2. Patient Group:

    • With other brain diseases without cerebral hemorrhage, cerebral ischemia, or brain edema;
    • With open craniocerebral injury;
    • With severe agitation.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No

Groups and cohorts

  • healthy group

    The healthy group included 16 individuals (male, age 40.25±11.18). No history of brain disease and no abnormalities were seen on plain CT scans of their brains.

    Diagnostic Test: multifrequency EIT-based for detecting intracranial abnormalities

  • patient group

    The patient group included 8 patients with brain diseases (7 males, age 59±10.46). Obvious lesions were visible on the patients' CT or MRI images, including 6 patients with intracranial hemorrhage, 1 patient with cerebral ischemia, and 1 patient with cerebral edema

    Diagnostic Test: multifrequency EIT-based for detecting intracranial abnormalities

Interventions

  • Diagnostic testmultifrequency EIT-based for detecting intracranial abnormalities

    For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.

06

What researchers measure

Primary outcomes

  1. Whether there is a significant difference in the characteristic indicators (such as symmetry indicators) of multifrequency EIT images between healthy individuals and patients with brain diseases.

    When there are significant differences in these indicators (such as symmetry indicators) (p\<0.05), there is no need for further data collection

    Time frame: Up to 12 days after the patient's onset

07

Study locations

1 site
  • PLA Army Characteristic Medical Center
    Chongqing, Chongqing 400042, China
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05796349
Lead sponsor
Jieshi Ma
Responsible party
Jieshi Ma (Deputy Director of MedicaEngineering Department, Army Medical Center of PLA) — Sponsor-investigator
First posted
Apr 3, 2023
Start date
Jun 1, 2022
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Last update
Apr 3, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion